



Minutes of the IOCB Board Meeting No. 4/2018 on March 29, 2018

Present: Ullrich Jahn, Pavel Jungwirth, Pavlína Maloy Řezáčová, Radim Nencka, Tomáš Obšil, Radek Pohl, Petr Slaviček, Petr Svoboda, Pavel Šácha

Guests: Zdeněk Hostomský, Martin Fusek

Secretary: Irena Valterová

1. *Otto Wichterle premium.* Volodymyr V. Shvadchak from the group of Dmytro Yushchenko was nominated for Wichterle premium. All Board members voted in favour of this nomination.

2. *IOCB Applied Research.* Martin Fusek informed the Board on running projects in which IOCBTech and i&i Prague participate. Three licence agreements were signed (Merck, Novo Nordisk, and Dracen Pharmaceuticals + Johns Hopkins University), 3 more licences are in preparation (Gilead, Apptec, and Diana). For the joint venture with Dracen and JHU, i&i Prague invested 200,000 USD. Eleven projects are currently in preparation for technology transfer (Nencka, Polášek, Janeba, Rejman, Birkuš, Konvalinka 3x, Majer, Kudová, Starý). The Board appreciates the update provided by Martin Fusek.

Discussion: Change in strategy at IOCB Tech and i&i Prague. Based on the information obtained on the last joint Board meeting of the IOCB Board and the Supervisory Board on June 13th, 2017 and Martin Fusek's interview in the Bond last year, a change in the strategy was noted by the Board. Namely, IOCB internal projects are now commercialized by i&i, which were originally supposed to be managing external projects. Martin Fusek explained the new strategy such that IOCB Tech will be responsible for promoting IOCB internal projects to the point that licence agreements can be prepared. If a spin-off based on an IOCB project is decided to be formed, i&i will manage that project thereon and act as a co-investor.

A question was raised why is it important to look for external partners and investors not specializing in pharma for creating IOCB spin-offs. The director replied that external companies have knowledge in business, they know the commercial environment, have experience in searching for customers, and furthermore, the financial risks are split among investors.

3. *IOCB Strategy for Applied and Translational Research.* The board members further commented on the document. M. Fusek will include points requested by Board members and the document will be then finalized and posted on the IOCB website.

4. *Information from the meeting of the IOCB Supervisory Board.* U. Jahn and P. Jungwirth were invited by the head of the Supervisory Board to the meeting of the IOCB Supervisory Board on March 28, 2018. The main topic of the meeting were licence agreements that IOCB either signed in the past, or has prepared for signing in the near future. At that meeting an extensive discussion about the topic took place especially concerning the role of the Supervisory Board in approval of such agreements. At that meeting, the chair of the Supervisory Board emphasized that the IOCB Board has to be informed about all relevant activities of the management as defined in the law on the v.v.i. The IOCB Board will discuss the form in which it will ask the director to provide relevant information on IOCB activities per rollam and hand over the finalized document to the director at the next meeting in written form.

The next Board meeting will take place on April 18 at 9.30 in the director's meeting room.

April 11, 2018.